HBV treatment
    2.
    发明授权
    HBV treatment 有权
    HBV治疗

    公开(公告)号:US09080174B2

    公开(公告)日:2015-07-14

    申请号:US13882124

    申请日:2011-10-27

    IPC分类号: C07H21/04 C12N15/113

    摘要: RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

    摘要翻译: 提供RNA干扰(RNAi)试剂和使用RNAi试剂治疗个体中的乙型肝炎感染,以及含有RNAi试剂的药物组合物。 用于表达它们的RNAi剂或构建体用于抑制至少一种乙型肝炎病毒(HBV)基因的表达,其中每种试剂包含与从靶区转录的预测序列互补或基本上互补的效应序列。 在本发明的一些实施方案中,所述试剂具有多于一个效应序列; 其中所述多个效应子可以靶向相同基因和/或不同HBV基因的HBV基因的相同区域,不同(可能重叠的)区域。